Biogen has appointed Jane Grogan, executive vice president, head of research effective October 2, 2023. Grogan will be a member of Biogen’s Executive Committee reporting to Christopher Viehbacher, President, and CEO.

Grogan brings nearly two decades of experience leading biotech research, including fifteen years with Genentech. She most recently served as the chief scientific officer at Graphite Bio, a cell, and gene editing company. Prior to this, she served as chief scientific officer at ArsenalBio, a privately held programmable T cell therapy company.

During her time at Genentech, Grogan served in a number of increasingly senior roles across immunology and immuno-oncology, covering research strategies and drug development across RA, lupus, MS, IBD and cancer. As head of adaptive tumor immunity and principal scientist in cancer immunology discovery research at Genentech, Grogan’s research primarily delved into mechanisms of T cell activation, tolerance-induction, and epigenetic modifiers, adopting an integrative methodology combining bioinformatics, biology, and diagnostics.

“Dr. Grogan is a pioneering scientist whose groundbreaking discoveries at Genentech helped pave the way for development of targeted autoimmune and oncology therapies,” said Viehbacher.  I believe Jane will be a strong asset to Biogen as we seek to bring a greater number of innovative medicines to market faster and more effectively. Together with Dr. Priya Singhal, executive vice president and head of development, she will determine the company’s portfolio strategy with the aim of creating value and making decisions aligned with our scientific expertise and translational capabilities.”